Clinical trials · New York, NY
Other Solid Tumors clinical trials in New York
We’re tracking 314 recruiting other solid tumors studies with a site in or near New York — including Phase 1, Phase 1/Phase 2 and Phase 2 studies, each written for real people, not researchers.
Recruiting studies near New York
- NCT05487170RecruitingPhase 1/Phase 2
Early trial of RNK05047 for advanced cancers
This Phase 1/2 study tests an experimental medicine (RNK05047) in people with advanced solid tumors or diffuse large B‑cell lymphoma whose standard treatments haven’t worked or can’t be tolerated. It may help shrink tumors and improve control of the disease, but early-phase trials also focus on safety and dosing.
New York, New YorkAges 18 years+ - NCT06350539Recruiting
Personalized Cancer Models Research Study
This study aims to create personalized models (like miniature tumors in a dish) from your cells to better understand your cancer and find new ways to treat it. Both people with solid tumors and healthy volunteers are welcome to participate.
New York, New YorkAges 18 years+ - NCT07038343RecruitingPhase 1/Phase 2
Testing a new drug for advanced solid tumors
This trial tests a new drug called AVZO-1418, either alone or with other treatments, for people with advanced solid tumors that have spread or cannot be removed. The goal is to see if the drug is safe and effective against certain types of cancer.
New York, New YorkAges 18–75 - NCT07186842RecruitingPhase 1/Phase 2
Testing the safety of BNT329 for advanced CA19-9 positive tumors
This trial tests if the investigational drug BNT329 is safe and could help people with advanced solid tumors that make a marker called CA19-9. It is for those who have tried standard treatments and need new options.
New York, New YorkAges 18 years+ - NCT06060613RecruitingPhase 1/Phase 2
Engineered immune cells for advanced melanoma or lung cancer
This trial tests a new treatment called OBX-115, which uses a patient's own immune cells that are modified in a lab to better fight cancer. It is for people with advanced melanoma or non-small cell lung cancer that has not responded to standard treatments.
New York, New YorkAges 18 years+ - NCT02332668RecruitingPhase 1/Phase 2
Pembrolizumab for children with advanced, hard-to-treat cancer
This trial tests pembrolizumab (an immunotherapy that helps the body recognize and attack cancer) in children with advanced solid tumors or lymphoma that can’t be cured. It’s designed for kids who have already tried standard treatments or don’t have standard treatment options.
New York, New YorkAges 6 months–17 years - NCT06465069RecruitingPhase 1
Study of an experimental drug for advanced bladder and other cancers
This trial tests a new drug called LY4052031 for people with advanced or metastatic cancers, especially bladder cancer. The drug aims to slow or stop tumor growth. Doctors will check if it is safe and how well it works.
New York, New YorkAges 18 years+ - NCT07277413RecruitingPhase 1
Study of IDE892 for advanced solid tumors with MTAP deletion
This study tests a new drug called IDE892, alone or in combination, for people with advanced solid tumors that have a specific genetic change (MTAP deletion). The goal is to see if the drug is safe and whether it can shrink tumors.
New York, New YorkAges 18 years+ - NCT05902988RecruitingPhase 1/Phase 2
Study of VLS-1488 for advanced cancers
This early-phase study tests VLS-1488, a new cancer medicine, in people with advanced cancers that have limited treatment options. It may help by finding a safe dose and whether it can shrink or control tumors.
New York, New YorkAges 18 years+ - NCT07359820RecruitingPhase 2
Lirafugratinib for solid tumors with FGFR2 fusion
This trial tests a targeted drug called lirafugratinib for people with advanced solid tumors (not bile duct cancer) that have a specific FGFR2 gene change. The drug blocks the faulty protein from helping the cancer grow.
New York, New YorkAges 18 years+ - NCT06586515RecruitingPhase 1
Testing a new drug for cancers with KRAS G12D mutation
This trial tests a new pill (LY3962673) for people whose cancer has a specific DNA change called KRAS G12D. The drug aims to block the faulty protein that helps the cancer grow, and the study will look at safety and whether the tumor shrinks.
New York, New YorkAges 18 years+ - NCT04683250RecruitingPhase 1/Phase 2
RET-targeting drug study for advanced cancers with RET changes
This trial tests an “RET-inhibitor” medicine (TAS0953/HM06) for advanced solid tumors that have RET gene changes. It may help shrink tumors by blocking cancer growth signals from the RET gene.
New York, New YorkAges 18 years+ - NCT02693535RecruitingPhase 2
Targeted drug testing for advanced cancer with tumor gene changes
This trial tests whether FDA-approved targeted drugs can help people with advanced cancer whose tumors have specific gene changes. It aims to match your tumor's unique genetic profile to a drug that may work better for you.
New York, New YorkAges 12 years+ - NCT06953089RecruitingPhase 2
Combination therapy study for advanced solid tumors
This trial is testing two new drugs (DB-1311 with BNT327 or DB-1305) in people with certain advanced or metastatic solid tumors that have not responded to prior treatments. It aims to see if the combination shrinks tumors or slows cancer growth.
New York, New YorkAges 18 years+ - NCT04895709RecruitingPhase 1/Phase 2
Testing a new cancer drug for advanced solid tumors
This early-phase trial tests how well a new drug (BMS-986340) works alone and combined with other treatments in people with advanced solid tumors that have progressed despite standard care. It also studies tumor samples to look for biomarkers that may predict who benefits.
New York, New YorkAges 18 years+ - NCT07196644RecruitingPhase 2
A study of a new drug for certain cancers with a specific gene change
This trial tests a drug called telisotuzumab adizutecan for people whose cancer has a specific genetic change called MET amplification. It may help when standard treatments are no longer working.
New York, New YorkAges 12 years+ - NCT05985655RecruitingPhase 1/Phase 2
Study of GTAEXS617 for advanced solid tumors
This trial tests a new drug called GTAEXS617 for adults with certain advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective.
New York, New YorkAges 18 years+ - NCT06167317RecruitingPhase 1
Study of GS-0201 alone and combined for advanced solid tumors
This trial tests a new drug called GS-0201, either by itself or with other treatments, for people with advanced solid tumors. The goal is to see if it is safe and helpful.
New York, New YorkAges 18 years+ - NCT06162221RecruitingPhase 1/Phase 2
Study of RAS inhibitors for advanced RAS-mutated lung cancer
This trial tests new drugs that target specific RAS mutations in advanced non-small cell lung cancer. It's for people whose cancer has a KRAS G12C, G12D, or other RAS mutation and who have already tried standard treatments.
New York, New YorkAges 18 years+ - NCT06172478RecruitingPhase 2
HER3-DXd for advanced solid tumors after prior treatment
This trial tests a new targeted drug called HER3-DXd for people with several types of advanced solid tumors that have stopped responding to standard treatments. The drug is an antibody-drug conjugate, designed to deliver chemotherapy directly to cancer cells that have a protein called HER3 on their surface.
New York, New YorkAges 18 years+ - NCT04777994RecruitingPhase 1
Drug ABBV-CLS-484 for advanced cancers that lack options
This Phase 1 trial tests ABBV-CLS-484 in people with advanced or metastatic tumors when standard treatments have not worked or aren’t available. Because it’s an early study, the main goal is to find a safe dose and see how the cancer responds in different cancer types.
New York, New YorkAges 18 years+ - NCT07349537RecruitingPhase 1
Study of RMC-5127 for advanced KRAS G12V-mutant solid tumors
This trial tests a new drug called RMC-5127 for people with advanced solid tumors that have a specific KRAS G12V mutation. The study aims to see if this targeted therapy can help when other treatments have stopped working or caused side effects.
New York, New YorkAges 18 years+ - NCT05932862RecruitingPhase 1
Test drug XL309 for advanced tumors with HRR gene changes
This early-phase study tests XL309 (and sometimes a mix of XL309 with another treatment) in people whose advanced solid tumors have specific DNA-repair gene changes, such as BRCA1/2 or other HRR-related changes. It aims to see how well the drug works and what dose is safest for these cancers.
New York, New YorkAges 18 years+ - NCT04064359RecruitingPhase 1
Safety study of OBT076 for certain CD205+ solid tumors
This Phase 1 trial tests the safety of a new drug called OBT076 and looks for early signs it can help people with certain advanced (recurrent or metastatic) solid tumors that have a specific marker called CD205. You may be eligible if standard treatments are not available or no longer work, and your cancer meets lab and scan requirements.
New York, New YorkAges 18 years+
Hear when a new Other Solid Tumors trial opens near New York, NY
We’ll email you when one opens near New York, NY — at most once a week, no account needed, unsubscribe anytime.
Other Solid Tumors trials in other cities
Where these studies are running near New York
Institutions with a site for the recruiting other solid tumors studies listed above.
- Memorial Sloan Kettering Cancer Center · 10 studies
- Columbia University Irving Medical Center · 4 studies
- NYU Langone Health · 4 studies
- Icahn School of Medicine at Mount Sinai / Mount Sinai Hospital · 2 studies
- Avenzo Therapeutics Recruiting Site
- Call for Information (Investigational Site 0031)
- Clinical Research Alliance
- Cohen Children's Medical Center
What taking part in a other solid tumors study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting other solid tumors studies in New York.
Common questions
- Are there other solid tumors clinical trials near New York?
- Yes. We're currently tracking 314 recruiting other solid tumors studies with a site near New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a other solid tumors study near New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site near New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a other solid tumors trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New other solid tumors studies open near New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.